Brokerages Set Repligen Co. (NASDAQ:RGEN) PT at $190.25

Repligen Co. (NASDAQ:RGEN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $190.25.

Several research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a "hold" rating to a "buy" rating and cut their price target for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They issued a "neutral" rating for the company. Stephens reaffirmed an "overweight" rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Finally, Benchmark reissued a "hold" rating on shares of Repligen in a research note on Monday, August 5th.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company's stock, valued at approximately $3,190,969.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the company's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Repligen

Large investors have recently modified their holdings of the business. CWM LLC boosted its holdings in Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company's stock worth $66,000 after buying an additional 60 shares during the period. Toronto Dominion Bank boosted its holdings in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale grew its position in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 89 shares in the last quarter. Diversified Trust Co raised its stake in shares of Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after purchasing an additional 106 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its holdings in Repligen by 6.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company's stock worth $354,000 after purchasing an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $2.33 during midday trading on Friday, hitting $136.71. The stock had a trading volume of 596,332 shares, compared to its average volume of 671,548. The company's 50-day moving average price is $149.73 and its 200-day moving average price is $151.97. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.64 billion, a P/E ratio of 546.84, a price-to-earnings-growth ratio of 4.32 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company's revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 earnings per share. As a group, equities research analysts predict that Repligen will post 1.45 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.